Latest news

• Merck buys ArQule for $2.7bn in another cancer bolt-on deal

  trials, with recent fails including c-MET inhibitor tivantinib.

• Daiichi Sankyo to shut down German antibody unit U3

  Daiichi Sankyo is looking to new products such as novel oral anticoagulant (NOAC) Lixiana (edoxaban) - as well as pipeline candidates like tivantinib for liver cancer, quizartinib for leukaemia and mirogabalin for

• Daiichi Sankyo cuts a swathe through US workforce

  These include tivantinib for liver cancer - tipped by some analysts as a $600m product despite disappointing data in lung cancer - quizartinib for leukaemia and mirogabalin for fibromyalgia.

• Roche drug fails in lung cancer trial

  It remains to be seen whether the failed study has implications for other c-MET inhibitors in clinical trials, although the class has had other notable casualties, including ArQule's tivantinib

• Daiichi, ArQule cancer drug tivantinib flunks another trial

  Tivantinib is a first in-class inhibitor of MET, a receptor tyrosine kinase thought to play a role in the development of a number of human cancers. ... to proceed with further clinical development of tivantinib in this tumour type ". 14th January 2013.